Listed by the USPTO as NGUYEN, JOHN P
Tech Center 1600 • Art Units: 1619
This examiner grants 44% of resolved cases
NGUYEN, JOHN P is assigned to tech center 1600 and art unit 1619. The profile includes 408 resolved cases and a 43.9% allowance rate. The 41.8% interview lift is a strong positive signal, associating interviews with materially better allowance outcomes in this dataset. The median time to allowance is 1180 days, so prosecution strategy should address both substantive difficulty and an extended timing horizon.
The listed companies are Insmed Incorporated, CSP Technologies Inc., and BIO PROTECTANT TECHNOLOGIES, INC. The leading firms are PROCOPIO, CORY, HARGREAVES & SAVITCH LLP, BUCHALTER, and COSUD INTELLECTUAL PROPERTY SOLUTIONS, P.C. Interviews may deserve early and careful preparation, with claim amendments tied closely to the technical record. The resolved-case count supports useful historical review while warranting caution about overgeneralization.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18733769 | Medication for Alleviating Parkinson's Symptoms and Method of Administering | Non-Final OA | Individual inventor |
| 17210366 | METHOD TO DESTABALIZE CYSTEINE EXPOSED INFECTIOUS INFORMATION VECTORS | Final Rejection | Individual inventor |
| 16950189 | Medication for Alleviating Parkinson's Symptoms and Method of Administering | Final Rejection | Individual inventor |
| 19345725 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | Final Rejection | CSP TECHNOLOGIES, INC. |
| 19342419 | FABRIC MATERIAL INFUSED OR IMPREGNATED WITH ONE OR MORE BENEFICIAL AGENTS AND METHOD OF MAKING THEREOF | Final Rejection | BIO PROTECTANT TECHNOLOGIES, INC. |
| 17054441 | SELF-MANAGEABLE ABNORMAL SCAR TREATMENT WITH SPHERICAL NUCLEIC ACID (SNA) TECHNOLOGY | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18001896 | TREATMENT OF ATRIAL DYSFUNCTION | Final Rejection | MyoKardia, Inc. |
| 18525039 | METHODS OF ANTIBODY PRODUCTION | Final Rejection | AMGEN INC. |
| 17636209 | Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 18340484 | TOPICAL CHLORINE DIOXIDE TREATMENT FOR MAMMALIAN TEATS | Non-Final OA | ECOLAB USA INC. |
| 17235771 | BIOLOGICALLY ACTIVE DRY POWDER COMPOSITIONS AND METHOD OF THEIR MANUFACTURE AND USE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18658140 | ROACH GEL FORMULATIONS | Non-Final OA | S. C. JOHNSON & SON, INC. |
| 18073852 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | Non-Final OA | YALE UNIVERSITY |
| 18513377 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | Non-Final OA | Insmed Incorporated |
| 18034619 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | Non-Final OA | Insmed Incorporated |
| 17998694 | IMMUNE BOOSTER - SUPPLEMENT TREATMENT KIT AND METHODS OF USE | Final Rejection | Altered Labs LLC |
| 18256593 | COMPOSITIONS COMPRISING MOLECULES FOR CYSTIC FIBROSIS TREATMENT | Non-Final OA | UNiversity of Iowa Research Foundation |
| 18264815 | HYDROGEN WATER FOR PREVENTION OF ALCOHOLIC HEPATOPATHY | Final Rejection | NIHON TRIM CO., LTD. |
| 18413456 | COMPOSITIONS AND METHODS FOR TREATING FLATWORMS | Final Rejection | New Guinea Flatworm Spray, Inc. |
| 18282623 | A METHOD OF REDUCING METHANE PRODUCTION IN A RUMINANT ANIMAL | Non-Final OA | DIT AgTech Limited |
| 17784053 | TOPICAL DELIVERY OF RNA INTERFERENCE AGENTS USING IONIC LIQUID | Non-Final OA | CAGE BIO, INC. |
| 18128866 | WOUND HEALING AND TISSUE REPAIR COMPOSITION AND METHOD USING LOW MOLECULAR WEIGHT COLLAGEN AND BIOACTIVE GLASS | Non-Final OA | SANARA MEDTECH APPLIED TECHNOLOGIES, LLC |
| 18124977 | Window of Opportunity Skin Treatment Regimen and Composition for Preventing the Onset of or Treating Atopic Dermatitis | Final Rejection | UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND |
| 18174006 | Mollusc Barrier | Non-Final OA | Doff Portland Limited |
| 18066945 | TOPICAL PHARMACEUTICAL COMPOSITIONS | Final Rejection | Dermavant Sciences GmbH |
| 18001582 | Pharmaceutical Compositions Containing Enterokine Releasing Substances In Multiple Dosage Forms In Combination With Gelling Agents | Non-Final OA | APHAIA IP AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.9% of resolved applications examined by John P Nguyen were allowed (408 resolved cases), compared with 22.7% across Art Unit 1619 over the last five years.
This examiner's interview lift is +41.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by John P Nguyen took 1,180 days on average from filing to allowance.
John P Nguyen examines applications in Art Unit 1619 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
